Horizon Scanning Centre November Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688
|
|
- Giles Jennings
- 5 years ago
- Views:
Transcription
1 Horizon Scanning Centre November 2012 Faldaprevir with BI for chronic hepatitis C infection, genotype 1 SUMMARY NIHR HSC ID: 7688 This briefing is based on information available at the time of research and a limited literature search. It is not intended to be a definitive statement on the safety, efficacy or effectiveness of the health technology covered and should not be used for commercial purposes or commissioning without additional information. Faldaprevir is intended to be used in combination with BI for the treatment of genotype 1 chronic hepatitis infection. If licensed, it would provide an additional treatment option for this patient group in a regimen that does not include interferon. The true incidence of hepatitis C infection is unknown, however estimates suggest that there are approximately 173,000 chronically infected patients in England and Wales. Around five out of six patients are unaware of their infection status Approximately 17,000 patients are currently receiving treatment, of whom 45% (7,650) are infected with genotype 1. Around 30% of infected people develop cirrhosis of the liver within years, and some of these go on to develop hepatocellular carcinoma. Current standard of care for genotype 1 patients is a triple combination therapy of telaprevir or boceprevir in combination with peginterferon alfa and ribavirin. Faldaprevir in combination with BI is currently in phase II clinical trials comparing its effect on sustained virological response with and without ribavirin. This briefing presents independent research funded by the National Institute for Health Research (NIHR). The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health. NIHR Horizon Scanning Centre, University of Birmingham nihrhsc@contacts.bham.ac.uk Web:
2 TARGET GROUP Chronic hepatitis C (HCV) infection: genotype 1. TECHNOLOGY DESCRIPTION Faldaprevir (BI ) is a second-generation HCV NS3/4A protease inhibitor with highly potent in vitro activity against GT1a/1b subtypes and pharmacokinetics that permit once daily dosing 1. BI is an orally bioavailable, reversible, thumb pocket 1 non-nucleoside inhibitor (NNI) of the HCV NS5B polymerase with potent and specific antiviral activity in vitro 1. Drug resistance studies in cell culture have demonstrated that faldaprevir and BI have different resistance profiles, and early evidence suggests that using NS3/4A protease inhibitors and NS5B thumb pocket 1 NNI compounds in combination may reduce the selection of drug resistant variants 1. Faldaprevir is administered orally at 120mg once daily in treatment naive patients, and at 240mg once daily in treatment experienced patients, in combination with BI administered orally at 600mg three times daily, both with or without ribavirin. Faldaprevir and BI are also in phase II and phase III clinical trials for hepatitis C in combination with ribavirin and peginterferon alfa. INNOVATION and/or ADVANTAGES If licensed, faldaprevir with BI will provide an additional treatment option for this patient group in a regimen that does not include interferon. DEVELOPER Boehringer Ingelheim Limited. AVAILABILITY, LAUNCH OR MARKETING In phase III clinical trials. PATIENT GROUP BACKGROUND HCV is a member of the flaviviridae family of spherical, enveloped, positive-strand RNA viruses. There are six different HCV genotypes; genotype 1 is the most common and the most resistant to treatment 2. The virus is acquired primarily through percutaneous exposure to contaminated blood 3. Most acute infections with HCV are asymptomatic with only 20% developing overt hepatitis 4. Approximately 80% of people who are infected go on to develop chronic HCV 3, symptoms of which include malaise, weakness and anorexia 4. Chronic HCV is categorised as mild, moderate or severe depending on the extent of liver damage 3. Approximately 30% of infected people develop cirrhosis within years, and some of these develop hepatocellular carcinoma 3. End stage-liver disease or hepatocellular carcinoma may require liver transplantation 3. Factors known to increase the rate of 2
3 progression include age, ethnicity, male sex, excessive alcohol consumption and HIV coinfection 5. NHS or GOVERNMENT PRIORITY AREA This topic is relevant to: The Blood Borne Virus Action Plan for Wales Improving Outcomes: A Strategy for Cancer (2011). CLINICAL NEED and BURDEN OF DISEASE The true incidence of HCV infection is difficult to establish, however recent estimates suggest that there are 173,000 chronically infected HCV patients in England and Wales 6, of whom around 28,833 are diagnosed (five out of six chronic HCV patients are unaware of their infection status) 6. Estimates suggest that by 2020, around 4,200 people in England may need a liver transplant as a result of untreated hepatitis C 7. Currently, 17,000 patients are receiving treatment, of whom 45% (7,650) are infected with genotype 1 8. It is estimated that there will be 7,922 genotype 1 chronic HCV patients being treated in In , chronic HCV (ICD-10 B17.1, B18.2) was the primary cause of 2,967 hospital admissions in England, resulting in 2,688 bed days 9. In 2010, there were 166 deaths registered in England and Wales 10. PATIENT PATHWAY RELEVANT GUIDANCE NICE Guidance NICE technology appraisal in development. Hepatitis C (children and young people) peginterferon alfa and ribavirin. (ID373). Expected August NICE technology appraisal. Telaprevir for the treatment of genotype 1 chronic hepatitis C (TA252). April NICE technology appraisal. Boceprevir for the treatment of genotype 1 chronic hepatitis C (TA253). April NICE technology appraisal. Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (TA200). September NICE technology appraisal. Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106). August NICE technology appraisal. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (TA75). January NICE public health guidance in development. Hepatitis B and C ways to promote and offer testing to people at risk of infection. Expected December Other Guidance Department of Health. Hepatitis C: quick reference guide for primary care Royal College of General Practitioners. Guidance for the prevention, testing, treatment and management of hepatitis C in primary care Scottish Intercollegiate Guidelines Network. Management of hepatitis C. (92)
4 British Association of Sexual Health and HIV. United Kingdom national guideline on the management of the viral hepatitides A, B & C British Society of Gastroenterology. Guidance on the treatment of hepatitis C incorporating the use of pegylated interferon EXISTING COMPARATORS and TREATMENTS The choice of therapy for HCV is influenced by genotype. Patients with genotype 2 or 3 are usually treated with 24 weeks of peginterferon alfa and ribavirin. Patients with genotype 1 are treated with triple combination therapy for a duration influenced by pre-treatment factors (including cirrhosis) and response to therapy 21. All patients with chronic HCV (irrespective of the stage of the disease) are considered for therapy 5. Current treatment options include 3,12,13 : A combination of ribavirin and peginterferon alfa-2a or 2b. Telaprevir in combination with peginterferon alfa and ribavirin. Boceprevir in combination with peginterferon alfa and ribavirin. Successful treatment is usually indicated by a sustained virologic response (SVR), which is defined as undetectable serum HCV RNA 6 months after the end of treatment 3. The proportion of people with HCV genotype 1 who show SVR after finishing a course of treatment with peginterferon and ribavirin is about 40% to 50%, compared to approximately 75% to 85% of people with HCV genotype 2 or 3, and 50% to 75% for other genotypes (4,5, and 6) 3,14. EFFICACY and SAFETY Trial SOUND-C1, NCT , , ; faldaprevir in combination with BI , with or without ribavirin; phase II. SOUND-C2; faldaprevir and BI , with or without ribavirin; phase IIb. Sponsor Boehringer Ingelheim. Boehringer-Ingelheim. Status Ongoing. Complete. Source of Trial registry 22, other database 23. Manufacturer 24. information Location EU, USA, Australia and New Zealand. Not reported. Design Randomised, active controlled. Randomised. Participants n=513 (planned); aged years; chronic HCV; genotype 1; treatment naive. n=362; HCV infection; genotype 1. Schedule Randomised to: Arm 1: faldaprevir, oral, once daily, with BI and ribavirin, for 4 weeks. Arm 2: faldaprevir, oral, once daily, with BI , low dose, oral, three times daily, and ribavirin, for 4 weeks. Arm 3: faldaprevir, oral, once daily, with BI and ribavirin, for 16 weeks. Arm 4: faldaprevir, oral, once daily, with BI and ribavirin, for 28 weeks. Arm 5: faldaprevir, oral, once daily, with BI Randomised to: Arm 1: faldaprevir, 120mg, once daily with BI , 600mg, three times daily and ribavirin for 16 weeks. Arm 2: faldaprevir, 120mg, once daily with BI , 600mg, three times daily and ribavirin for 28 weeks. Arm 3: faldaprevir, 120mg, once daily with BI , 600mg, three times daily and ribavirin for 40 weeks. Arm 4: faldaprevir, 120mg, once daily with BI , 600mg, twice daily and ribavirin for 28 weeks. Arm 5: faldaprevir, 120mg, once daily with 4
5 Follow-up and ribavirin, for 40 weeks. Arm 6: faldaprevir, oral, once daily, with BI , high dose, oral, twice daily, and ribavirin, for 28 weeks. Arm 7: faldaprevir, oral, once daily, with BI for 28 weeks. Arm 8: faldaprevir, oral, once daily, with BI , high dose, oral, twice daily, and ribavirin, for 16 weeks. Arm 9: faldaprevir, oral, once daily, with BI , very high dose, oral, twice daily, and ribavirin, for 24 weeks. Arm 10: faldaprevir, oral, once daily, with BI , high dose, oral, three times daily, and ribavirin, for 24 weeks. Active treatment up to 40 weeks; follow-up period not reported BI , 600mg, three times daily for 28 weeks. Active treatment period up to 40 weeks; follow-up period not reported. Primary Rapid virological response (RVR); SVR. outcome/s sustained virologic response (SVR). Secondary Time to virological response. Not reported. outcome/s Key results - For arms 1-5 respectively, SVR (%), genotype 1a: 38, 44, 47, 43, 11; genotype 1b: 75, 69, 56, 85, 57. Adverse effects (AEs) - Most common AEs included skin changes (photosensitivity, rash), gastrointestinal disorders (vomiting, diarrhoea), jaundice due to transient benign bilirubin elevation (unconjugated hyperbilirubinemia). Expected reporting date Not reported. - ESTIMATED COST and IMPACT COST The cost of faldaprevir in combination with BI is not yet known. The costs of selected currently licensed treatments for HCV are summarised below 25 : Drug Dose a 12 week cost 48 week cost Peginterferon alfa-2a (Pegasys) 180µg SC once weekly 1, , Peginterferon alfa-2b (ViraferonPeg) 100µg SC once weekly 1, , Ribavirin (Rebetol) 1,000mg daily , Telaprevir (Incivo) 2,250mg daily 22, n/a Bopeprevir (Victrelis) 2,400mg daily 8, ,400 b a Based on an average weight of 77.9kg (men and women). b Indicated for 32 weeks treatment. 5
6 IMPACT - SPECULATIVE Impact on Patients and Carers Reduced mortality/increased length of survival Reduced symptoms or disability Other: potential shortened course of treatment compared to standard of care, without the side effects associated with peginterferon; oral regimen has the potential improve adherence. Impact on Services No impact identified Increased use of existing services Decreased use of existing services Re-organisation of existing services Need for new services Other: IL28b testing may be required to determine suitability for treatment. None identified Impact on Costs Increased drug treatment costs Reduced drug treatment costs Other increase in costs:. Other reduction in costs: Other: uncertain unit cost compared to existing treatments None identified Other Issues Clinical uncertainty or other research question identified: expert opinion suggests there is a lack of data on the comparative efficacy of the directly acting antiviral drugs currently in development. Expert opinion also highlights a lack of data on efficacy in patients previously treated with boceprevir or telaprevir (cross resistance with faldaprevir is reported). c REFERENCES None identified 1 Zeuzem S, Asselah T, Angus P et al. Efficacy of the protease inhibitor BI , polymerase inhibitor BI , and Ribavirin in patients with chronic HCV infection. Gasteroenterology 2011;141(6): Mohsen A, Norris S. Hepatitis C (chronic). Clinical Evidence 2010;02: National Institute for Health and Clinical Excellence. Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. Technology appraisal TA200. London: NICE; September National Institute for Health and Clinical Excellence. Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. Technology appraisal TA106. London: NICE; August Royal College of General Practitioners. Guidance for the prevention, testing, treatment and management of hepatitis C in primary care. London: RCGP; May Health Protection Agency. Hepatitis C in the UK: 2011 report. London: HPA; July Health Protection Agency. Four thousand people in England may need liver transplants by 2020 due to hepatitis C, HPA warns. yleadtotransplantneeds/ Accessed 5 November c Expert personal communication. 6
7 8 National Institute for Health and Clinical Excellence. Single technology appraisal (STA). Telaprevir for the treatment of genotype 1 chronic hepatitis C. London: NICE; October NHS. Hospital episode statistics. NHS England HES data Office for National Statistics. Mortality Statistics: Deaths registered in England and Wales, series DR National Institute for Health and Clinical Excellence. Hepatitis C (children and young people) peginterferon alfa and ribavirin. Technology appraisal in development ID373. Expected August National Institute for Health and Clinical Excellence. Telaprevir for the treatment of genotype 1 chronic hepatitis C. Technology appraisl TA252. London: NICE; April National Institute for Health and Clinical Excellence. Boceprevir for the treatment of genotype 1 chronic hepatitis C. Technology appraisal TA253. London: NICE; April National Institute for Health and Clinical Excellence. Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C. Technology appraisal TA106. London: NICE; August National Institute for Health and Clinical Excellence. Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C. Technology appraisal TA75. London: NICE; January National Institute for Health and Clinical Excellence. Hepatitis B and C ways to promote and offer testing to people at risk of infection. Public health guidance in development. Expected December Department of Health. Hepatitis C: quick reference guide for primary care. London; Crown; January Scottish Intercollegiate Guidelines Network. Management of hepatitis C. National clinical guideline 92. Edinburgh: SIGN; December British Association of Sexual Health and HIV. United Kingdom national guideline on the management of the viral hepatitis A, B & C London: BASHH; September British Society of Gastroenterology. Guidance on the treatment of Hepatitis C incorporating the use of pegylated interferons. London: BSG; March National Institute for Health Research Horizon Scanning Centre. Simeprevir for chronic hepatitis C infection. Birmingham: NIHR HSC; September ClinicalTrials.gov. Safety, antiviral effect and PK of BI BI /- RBV for 4 up to 40 weeks in patients with chronic HCV genotype 1 infection. Accessed 5 November PharmaProjects. Faldaprevir. Accessed 28 November Boehringer-Ingelheim. Phase 2b data of Boehringer Ingelheim s interferon-free hepatitis C treatment show viral cure achieved in up to 85% of treatment-naïve patients. Accessed 28 November British Medical Association and Royal Pharmaceutical Society of Great Britain. British National Formulary. BNF 64. London: BMJ Group and RPS Publishing, September
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C. Part review of NICE technology appraisal guidance 75 and 106
Issue date: September 2010 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C Part review of NICE technology appraisal guidance 75 and 106 National Institute for Health and Clinical
More informationTechnology appraisal guidance Published: 22 September 2010 nice.org.uk/guidance/ta200
Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C Technology appraisal guidance Published: 22 September 2010 nice.org.uk/guidance/ta200 NICE 2018. All rights reserved. Subject to
More informationLiraglutide (Victoza) in combination with basal insulin for type 2 diabetes
Liraglutide (Victoza) in combination with basal insulin for type 2 diabetes May 2011 This technology summary is based on information available at the time of research and a limited literature search. It
More informationCertolizumab pegol (Cimzia) for psoriatic arthritis second line
Certolizumab pegol (Cimzia) for psoriatic arthritis second line This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationCilengitide (Impetreve) for glioblastoma multiforme. February 2012
Cilengitide (Impetreve) for glioblastoma multiforme February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationLacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011
Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a
More informationHorizon Scanning Centre November Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887
Horizon Scanning Centre November 2012 Vinflunine (Javlor) monotherapy for advanced breast cancer SUMMARY NIHR HSC ID: 7887 This briefing is based on information available at the time of research and a
More informationHorizon Scanning Centre November Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line
Horizon Scanning Centre November 2012 Enobosarm (Ostarine) for cachexia in patients with advanced non-small cell lung cancer first line SUMMARY NIHR HSC ID: 5206 This briefing is based on information available
More informationHorizon Scanning Centre November Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330
Horizon Scanning Centre November 2012 Secukinumab for active and progressive psoriatic arthritis. SUMMARY NIHR HSC ID: 5330 Secukinumab is a high-affinity fully human monoclonal antibody that antagonises
More informationInsulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes
Insulin degludec/insulin aspart (DegludecPlus) for type 1 diabetes This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationScottish Medicines Consortium
Scottish Medicines Consortium pegylated interferon α 2b (ViraferonPeg ), 50, 80, 100, 120 or 150 micrograms powder for solution for injection in pre-filled pen, in combination with ribavirin (Rebetol ),
More informationHorizon Scanning Centre March Denosumab for glucocorticoidinduced SUMMARY NIHR HSC ID: 6329
Horizon Scanning Centre March 2014 Denosumab for glucocorticoidinduced osteoporosis SUMMARY NIHR HSC ID: 6329 This briefing is based on information available at the time of research and a limited literature
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 14 December 2011
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 14 December 2011 INCIVO 375 mg, film-coated tablet B/4 bottles of 42 tablets (CIP code: 217 378-5) B/1 bottle of 42
More informationHorizon Scanning Technology Summary. Tenofovir disoproxil fumarate for hepatitis B. National Horizon Scanning Centre. April 2007
Horizon Scanning Technology Summary National Horizon Scanning Centre Tenofovir disoproxil fumarate for hepatitis B April 2007 This technology summary is based on information available at the time of research
More informationOlesoxime for amyotrophic lateral sclerosis first line
Olesoxime for amyotrophic lateral sclerosis first line May 2011 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationHorizon Scanning Centre November 2012
Horizon Scanning Centre November 2012 Cangrelor to reduce platelet aggregation and thrombosis in patients undergoing percutaneous coronary intervention99 SUMMARY NIHR HSC ID: 2424 This briefing is based
More informationHorizon Scanning Centre November Spheroids of human autologous matrix-associated chondrocytes (Chondrosphere) for articular cartilage defects
Horizon Scanning Centre November 2014 Spheroids of human autologous matrix-associated chondrocytes (Chondrosphere) for articular cartilage defects SUMMARY NIHR HSC ID: 8515 This briefing is based on information
More informationApixaban for stroke prevention in atrial fibrillation. August 2010
Apixaban for stroke prevention in atrial fibrillation August 2010 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to
More informationHorizon Scanning Centre March Cholic acid (Orphacol) for inborn errors of primary bile acid synthesis first line SUMMARY NIHR HSC ID: 9468
Horizon Scanning Centre March 2014 Cholic acid (Orphacol) for inborn errors of primary bile acid synthesis first line SUMMARY NIHR HSC ID: 9468 This briefing is based on information available at the time
More informationHEPATITIS C TREATMENT GUIDANCE
HEPATITIS C TREATMENT GUIDANCE These guidelines have been produced based on the NICE Guidance TA200 Peginterferon alfa and ribavirin for the treatment of chronic hepatitis c and the summaries of product
More informationInformation Magazine for people with Hepatitis C and HIV. Hepatitis C - Treatment in people with haemophilia, the results to date
Positive News Information Magazine for people with Hepatitis C and HIV Hepatitis C - Treatment in people with haemophilia, the results to date From July 2012 to October 2013, a total of fifteen persons
More informationSECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM
SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN SECTION 2: OLYSIO with (PEGINTRON) AND RIBAVIRIN RATIONALE FOR INCLUSION IN PA PROGRAM SECTION 1: OLYSIO with (PEGASYS) AND RIBAVIRIN Background Hepatitis
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta363
Ledipasvir sofosbuvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta363 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationSafety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus
Safety of Treatment in Cirrhotics in the Era of New Antiviral Therapies for Hepatitis C Virus JEFFREY NADELSON MD, ALAN EPSTEIN MD, THOMAS SEPE MD BOSTON UNIVERSITY SCHOOL OF MEDICINE ROGER WILLIAMS MEDICAL
More informationAssessment of sofosbuvir (Sovaldi )
Assessment of sofosbuvir (Sovaldi ) Summary of the national assessments of sofosbuvir (Sovaldi ) for the treatment of Hepatitis C December 18, 2014 Health Care Institute, Diemen, NL Lead Partner WP5 EUnetHTA
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal (STA)
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Single Technology Appraisal (STA) Telaprevir for the treatment of genotype 1 chronic hepatitis C 21 st October 2011 Page 1 of 239 Contents Contents...
More informationExpress Scripts, Inc. monograph dated 5/25/2011; selected revision 6/1/2011
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Coverage Criteria: Approval Period: Victrelis (boceprevir capsules)
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364
Daclatasvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta364 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationAntiviral agents in HCV
Antiviral agents in HCV : Upcoming Therapeutic Options Su Jong Yu, M.D., Ph.D. Department of Internal Medicine, Liver Research Institute, Seoul National University College of Medicine Estimated 170 Million
More informationOral combination therapy: future hepatitis C virus treatment? "Lancet Oct 30;376(9751): Oral combination therapy with a nucleoside
Author manuscript, published in "Journal of Hepatology 2011;55(4):933-5" DOI : 10.1016/j.jhep.2011.04.018 Oral combination therapy: future hepatitis C virus treatment? Commentary article on the following
More informationOlysio Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.28 Subject: Olysio Pegasys Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio Pegasys
More informationHarvoni: solution to HCV
Harvoni: solution to HCV PRESENTATION BY: PATRICK HO, USC PHARM D. CANDIDATE OF 2017 MENTOR: DR. CRAIG STERN, PHARMD, MBA, RPH, FASCP, FASHP, FICA, FLMI, FAMCP Hepatitis C (HCV) Inflammation of the liver,
More informationCertolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line
Certolizumab pegol (Cimzia) for the treatment of ankylosing spondylitis second or third line August 2011 This technology summary is based on information available at the time of research and a limited
More informationOlysio PegIntron Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.27 Subject: Olysio PegIntron Ribavirin Page: 1 of 7 Last Review Date: March 18, 2016 Olysio PegIntron
More informationNational Horizon Scanning Centre. Transient elastography (FibroScan) for evaluating liver fibrosis. April 2008
Transient elastography (FibroScan) for evaluating liver fibrosis April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not
More informationPhase 3. Treatment Experienced. Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2. Afdhal N, et al. N Engl J Med. 2014;370:
Phase 3 Treatment Experienced Ledipasvir-Sofosbuvir +/- Ribavirin in HCV Genotype 1 ION-2 Afdhal N, et al. N Engl J Med. 2014;370:1483-93. Ledipasvir-Sofosbuvir +/- Ribavirin in Treatment-Experienced HCV
More informationSimeprevir + PEG + RBV in Treatment-Naïve Genotype 1 QUEST-1 Trial
Phase 3 Treatment Naïve Simeprevir + in Treatment-Naïve Genotype 1 QUEST-1 Trial Jacobson IM, et al. Lancet. 2014;384:403-13. Simeprevir + PEG + Ribavirin for Treatment-Naïve HCV GT1 QUEST-1 Trial QUEST-1
More informationCabozantinib for medullary thyroid cancer. February 2012
Cabozantinib for medullary thyroid cancer February 2012 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive
More informationEASL 2013 Interferon Free, All Oral Regimens for Hepatitis C. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain
EASL 2013 Interferon Free, All Oral Regimens for Hepatitis C Maria Buti Hospital Universitario Valle Hebron Barcelona Spain The first Results with Oral therapy: a Protease Inhibitor and NS5A inhibitor
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 16 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationAppendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors.
Appendix This appendix was part of the submitted manuscript and has been peer reviewed. It is posted as supplied by the authors. Appendix to: Thompson AJV; Expert panel representing the Gastroenterological
More informationPasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line
Pasireotide Long-Acting Repeatable (Signifor) for acromegaly first and second line December 2010 This technology summary is based on information available at the time of research and a limited literature
More informationResource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430
Putting NICE guidance into practice Resource impact report: Sofosbuvir velpatasvir for treating chronic hepatitis C TA430 Published: January 2017 Summary Sofosbuvir velpatasvir is recommended as an option
More informationHepatitis C Virus Clinical Criteria Update September 18, For: New York State Medicaid
Hepatitis C Virus Clinical Criteria Update September 18, 2014 For: New York State Medicaid 1 Purpose Characterize the place in therapy for the agents utilized for management of chronic hepatitis C (CHC)
More informationUstekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs)
Ustekinumab (Stelara) for psoriatic arthritis second line after disease modifying anti rheumatic drugs (DMARDs) January 2010 This technology summary is based on information available at the time of research
More informationREQUEST FOR INFORMATION - HEPATITIS C TREATMENTS
10 August 2015 REQUEST FOR INFORMATION - HEPATITIS C TREATMENTS PHARMAC is seeking information from suppliers of novel direct-acting antiviral agents (DAAs) for the treatment of hepatitis C. This Request
More informationECONOMIC ANALYSIS TO SUPPORT NHS IMPLEMENTATION OF HEPATITIS C DRUGS: SCOPING STUDY
Policy Research Unit in Economic Evaluation of Health & Care Interventions (EEPRU) ECONOMIC ANALYSIS TO SUPPORT NHS IMPLEMENTATION OF HEPATITIS C DRUGS: SCOPING STUDY May 2015 Report 046 Authors: Rita
More informationNational Horizon Scanning Centre. GV1001 for advanced and/or metastatic pancreatic cancer. April 2008
GV1001 for advanced and/or metastatic pancreatic cancer April 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationTechnology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta365
Ombitasvir paritaprevir ritonavir with or without dasabuvir for treating chronic hepatitis C Technology appraisal guidance Published: 25 November 2015 nice.org.uk/guidance/ta365 NICE 2017. All rights reserved.
More informationHTA: Models, Costs & Benefits.
HTA: Models, Costs & Benefits John.Cairns@lshtm.ac.uk Explicit evaluation of costs and benefits Advantages Potential for more consistent decision making Potential for more transparent decision making Facilitates
More informationNational Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008
Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis June 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More informationB-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma
B-cell lymphoma vaccine (BiovaxID) for follicular non-hodgkin s lymphoma May 2010 This technology summary is based on information available at the time of research and a limited literature search. It is
More informationFrom 19 February 2015
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment pharmaceuticals with new active ingredients, in accordance
More informationKTE-C19 for relapsed or refractory mantle cell lymphoma
NIHR Innovation Observatory Evidence Briefing: July 2017 KTE-C19 for relapsed or refractory mantle cell lymphoma NIHRIO (HSRIC) ID: 11846 NICE ID: 9122 LAY SUMMARY Mantle cell lymphoma is an uncommon type
More informationPharmacological management of viruses in obese patients
Cubist Pharmaceuticals The Shape of Cures to Come Pharmacological management of viruses in obese patients Dr. Dimitar Tonev, Medical Director UKINORD 1 Disclosures } The author is a pharmaceutical physician
More informationTechnology appraisal guidance Published: 27 November 2013 nice.org.uk/guidance/ta300
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people Technology appraisal guidance Published: 27 November 2013 nice.org.uk/guidance/ta300 NICE 2018. All rights
More informationAbout the National Centre for Pharmacoeconomics
Cost effectiveness of sofosbuvir (in combination with either ribavirin or pegylated interferon + ribavirin) (Sovaldi ) for the treatment of hepatitis C infection The NCPE has issued a recommendation regarding
More informationIntroduction. The ELECTRON Trial
63rd AASLD November 9-13, 12 Boston, Massachusetts Faculty Douglas T. Dieterich, MD Professor of Medicine and Director of CME Department of Medicine Director of Outpatient Hepatology Division of Liver
More informationledipasvir/sofosbuvir, 90mg/400mg, film-coated tablet (Harvoni ) SMC No. (1030/15) Gilead Sciences Ltd
ledipasvir/, 90mg/400mg, film-coated tablet (Harvoni ) SMC No. (1030/15) Gilead Sciences Ltd 06 February 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and
More information2017 UnitedHealthcare Services, Inc.
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1146-7 Program Prior Authorization/Notification Medication Harvoni (ledipasvir/sofosbuvir) P&T Approval Date 10/2014, 2/2015,
More informationBotulinum toxin A (Dysport) for hyperhidrosis of the axillae
April 2016 Horizon Scanning Research & Intelligence Centre Botulinum toxin A (Dysport) for hyperhidrosis of the axillae LAY SUMMARY This briefing is based on information available at the time of research
More informationTopic: Sovaldi, sofosbuvir Date of Origin: March 14, Committee Approval Date: August 15, 2014 Next Review Date: March 2015
Medication Policy Manual Policy No: dru332 Topic: Sovaldi, sofosbuvir Date of Origin: March 14, 2014 Committee Approval Date: August 15, 2014 Next Review Date: March 2015 Effective Date: October 1, 2014
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 4
National Clinical Guidelines for the treatment of HCV in adults Version 4 November 2017 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN
More informationfrom 29 March 2012 Effect estimates [95% CI] Telaprevir + PegIFN/RBV vs. PegIFN/RBV
Resolution by the Federal Joint Committee on an amendment to the Pharmaceutical Directive (AM-RL): Appendix XII Resolutions on the benefit assessment of pharmaceuticals with new active ingredients, in
More informationSpecial Contribution Highlights of the 2012 American Association for the Study of Liver Diseases Meeting
Special Contribution Highlights of the 20 American Association for the Study of Liver Diseases Meeting Melissa K. Osborn, MD The American Association for the Study of Liver Diseases (AASLD) held its annual
More informationClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, ClinicalTrials.gov ID: NCT
ClinicalTrials.gov Protocol Registration and Results System (PRS) Receipt Release Date: June 25, 2014 ClinicalTrials.gov ID: NCT00372385 Study Identification Unique Protocol ID: VX05-950-104EU Brief Title:
More informationTreatment of Hepatitis C in HIV-Coinfected Patients. Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain
Treatment of Hepatitis C in HIV-Coinfected Patients Vincent Soriano Department of Infectious Diseases Hospital Carlos III Madrid, Spain Estimated no. of persons infected with HIV and hepatitis viruses
More informationHCV Case Study. Treat Now or Wait for New Therapies
HCV Case Study Treat Now or Wait for New Therapies This program is supported by educational grants from Kadmon and Merck Pharmaceuticals. Program Disclosure This activity has been planned and implemented
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 3
National Clinical Guidelines for the treatment of HCV in adults Version 3 January 2017 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN
More informationNational Clinical Guidelines for the treatment of HCV in adults. Version 5
National Clinical Guidelines for the treatment of HCV in adults Version 5 June 2018 Sponsors and Authorship The guidelines have been authored on behalf of the viral hepatitis clinical leads and MCN co-ordinators
More informationCost effectiveness of sofosbuvir and ledipasvir (Harvoni ) in combination with other medicinal products for the treatment of hepatitis C infection
Cost effectiveness of sofosbuvir and ledipasvir (Harvoni ) in combination with other medicinal products for the treatment of hepatitis C infection The NCPE has issued a recommendation regarding the cost
More informationEverolimus (Votubia) for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis first line or post surgery
Everolimus (Votubia) for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis first line or post surgery April 2011 This technology summary is based on information
More informationOlysio Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.28 Subject: Olysio Pegasys Ribavirin Page: 1 of 8 Last Review Date: December 18, 2017 Olysio Pegasys
More informationGlecaprevir-Pibrentasvir in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2)
Phase 3 Treatment-Experienced in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2) in HCV GT 1 or 4 & Prior DAA Treatment MAGELLAN-1 (Part 2): Study Features MAGELLAN-1 (Part 2) Trial Design: Randomized,
More informationHepatitis C Resistance Associated Variants (RAVs)
Hepatitis C Resistance Associated Variants (RAVs) Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Nothing to disclose Disclosure
More informationTreatment of Hepatitis C with sofosbuvir/ledipasvir (Harvoni )
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationNew developments in HCV research and their implications for front-line practice
New developments in HCV research and their implications for front-line practice Dr. Curtis Cooper Associate Professor, University of Ottawa Director, Ottawa Hospital Viral Hepatitis Program June 17, 2013
More informationNATIONAL INSTITUTE FOR CLINICAL EXCELLENCE. Final Appraisal Determination
NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE Final Appraisal Determination Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C 1 Guidance 1.1 Combination
More informationThe HCV pipeline: Will IFN-free treatment be possible? Heiner Wedemeyer. Hannover Medical School Germany
: Will IFN-free treatment be possible? Heiner Wedemeyer Hannover Medical School Germany Interferon-free regimens to treat hepatitis C What should be the goal of interferon-free treatment regimens: Sustained
More informationStick or twist management options in hepatitis C
Stick or twist management options in hepatitis C Dr. Chris Durojaiye & Dr. Matthijs Backx SpR Microbiology and Infectious Diseases University Hospital of Wales, Cardiff Patient history 63 year old female
More informationThe role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients
The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1na «ve patients David R. Nelson Clinical and Translational Science Institute, University of Florida, FL, USA Liver International
More informationCabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel
Cabazitaxel (XRP-6258) for hormone refractory, metastatic prostate cancer second line after docetaxel April 2009 This technology summary is based on information available at the time of research and a
More informationUpdate in the Management of Hepatitis C: What Does the Future Hold
Update in the Management of Hepatitis C: What Does the Future Hold Paul Y Kwo, MD, FACG Professor of Medicine Mdi Medical ldirector, Liver Transplantation tti Gastroenterology/Hepatology Division Indiana
More informationProtease inhibitor based triple therapy in treatment experienced patients
Protease inhibitor based triple therapy in treatment experienced patients Universitätsklinikum Leipzig Thomas Berg Sektion Hepatologie Klinik und Poliklinik für Gastroenterologie und Rheumatologie Leber
More informationTHE CHANGING LANDSCAPE OF HEPATITIS INFECTION. Michael E. Herman D.O.
THE CHANGING LANDSCAPE OF HEPATITIS INFECTION Michael E. Herman D.O. What s New? For Primary Care Providers Importance of diagnosing HCV For HCV Treaters How can we improve current therapies? For everyone
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency London, 24 April 2008 Doc. Ref. EMEA/CHMP/EWP/30039/2008 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE CLINICAL EVALUATION OF DIRECT ACTING ANTIVIRAL
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the clinical
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Hepatitis C First Generation Agents Page 1 of 18 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: See also: Hepatitis C First Generation Agents - Through Preferred
More informationRoflumilast (Daxas) for chronic obstructive pulmonary disease
Roflumilast (Daxas) for chronic obstructive pulmonary disease August 2009 This technology summary is based on information available at the time of research and a limited literature search. It is not intended
More information5/12/2016. Learning Objectives. Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients
5/12/216 Management of Hepatitis C Virus Genotype 2 or 3 Infected Treatment-Naive or Experienced Patients Alexander Monto, MD Professor of Clinical Medicine University of California San Francisco San Francisco,
More informationNovember 2013 AASLD Investor Event 4 November
November 2013 AASLD Investor Event 4 November Maris Hartmanis, President and CEO Charlotte Edenius, EVP Development Bertil Samuelsson, CSA Rein Piir, EVP Corporate Affairs & IR Corporate presentation,
More informationHorizon Scanning Centre March Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798
Horizon Scanning Centre March 2015 Tildrakizumab for moderate to severe plaque psoriasis SUMMARY NIHR HSC ID: 6798 This briefing is based on information available at the time of research and a limited
More informationTechnology appraisal guidance Published: 28 January 2004 nice.org.uk/guidance/ta75
Interferon alfa (pegylated and non- pegylated) and ribavirin for the treatment of chronic hepatitis C Technology appraisal guidance Published: 28 January 2004 nice.org.uk/guidance/ta75 NICE 2017. All rights
More informationDirect acting anti-virals: the near future
Direct acting anti-virals: the near future Heiner Wedemeyer Hannover Medical School Germany Will IFN-free treatment be possible in the near future? Interferon-free regimens to treat hepatitis C What should
More informationProgram Disclosure. Provider is approved by the California Board of Registered Nursing, Provider #13664, for 1.5 contact hours.
Program Disclosure This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint-sponsorship
More informationTreatment of Hepatitis C with simeprevir (Olysio ) PLUS sofosbuvir (Sovaldi ) Archived Medical Policy
Treatment of Hepatitis C with simeprevir (Olysio ) PLUS sofosbuvir (Sovaldi ) Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana,
More informationDr Janice Main Imperial College Healthcare NHS Trust, London
BHIVA AUTUMN CONFERENCE 2014 Including CHIA Parallel Sessions Dr Janice Main Imperial College Healthcare NHS Trust, London 9-10 October 2014, Queen Elizabeth II Conference Centre, London BHIVA AUTUMN CONFERENCE
More informationThe Changing World of Hepatitis C
The Changing World of Hepatitis C Alnoor Ramji Gastroenterology & Hepatology Clinical Associate Professor Division of Gastroenterology University Of British Columbia St. Paul s Hospital Site Disclosures
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationEntecavir for the treatment of chronic hepatitis B infection
DOI: 10.3310/hta13suppl3/05 Health Technology Assessment 2009; Vol. 13: Suppl. 3 Entecavir for the treatment of chronic hepatitis B infection J Shepherd,* E Gospodarevskaya, G Frampton and K Cooper Southampton
More information